| 30 Sept 2026, 16:05 | Audited Financial Statements | Financial Results | — | 03001, 03002, 03011, 03012, 03013, 03020 |
| 14 Sept 2026, 08:23 | SOF-SKN to progress to extension study in CLE patients | Company Update | — | 11001 |
| 4 Sept 2026, 08:11 | Investor Presentation September 2026 | Presentations | — | 03026 |
| 1 Sept 2026, 09:36 | Novel oligonucleotides data presented at Options Conference | Company Update | MS | 11001 |
| 28 Aug 2026, 16:34 | Appendix 4E - Preliminary Financial Report | Financial Results | MS | 03003 |
| 26 Aug 2026, 08:06 | New preclinical data supports immuno-oncology approach | Company Update | MS | 11001 |
| 4 Aug 2026, 08:18 | New study further validates Noxopharms cancer pipeline | Company Update | — | 11001 |
| 22 July 2026, 08:26 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19004, 19009 |
| 7 July 2026, 09:34 | Pre-IND meeting request with US FDA | Company Update | — | 11001 |
| 2 July 2026, 08:15 | Sofr platform versatility shown via childbirth MRFF grant | Company Update | — | 11001, 12008 |
| 1 July 2026, 09:50 | Fast-tracking of cancer program via novel animal model | Company Update | — | 11001 |
| 9 June 2026, 08:29 | SOF-SKN manufacturing begins to ensure clinical trial readi | Company Update | MS | 11001 |
| 1 June 2026, 16:23 | Change of Director's Interest Notice | Director Interests | — | 02009 |
| 26 May 2026, 08:21 | New data confirms cancer-fighting potential | Company Update | MS | 11001 |
| 20 May 2026, 09:21 | Noxopharms Sofra assets to be presented at global conference | Company Update | MS | 11001 |
| 8 May 2026, 09:28 | Proposed issue of securities - NOX | Securities Administration | — | 06013 |
| 6 May 2026, 08:13 | Noxopharm progresses US regulatory strategy | Company Update | MS | 11001 |
| 1 May 2026, 09:08 | New data shows SOF-SKN active ingredient efficacy | Company Update | MS | 11001 |
| 30 Apr 2026, 08:18 | New Company Secretary appointed | Company Administration | — | 12007 |
| 27 Apr 2026, 08:21 | Innovative collaboration further expands Sofra platform | Company Update | MS | 11001 |
| 24 Apr 2026, 09:23 | March 2026 Quarterly Activities Report and Appendix 4C | Quarterly Reports | MS | 19003, 19008 |
| 22 Apr 2026, 08:35 | Positive SOF-SKN dosing data shows prolonged skin retention | Company Update | MS | 11001 |
| 15 Apr 2026, 09:27 | Noxopharm appoints Dr Olivier Laczka as new CEO | Company Administration | MS | 12019 |
| 15 Apr 2026, 09:22 | Change of & Final Directors Interest Notice (App 3Y & 3Z)-GM | Director Interests | — | 02009, 02010 |
| 14 Apr 2026, 09:55 | Resignation of Chief Executive Officer | Company Administration | MS | 12019 |
| 27 Feb 2026, 13:40 | Appendix 4D and FY2026 Half Year Financial Report | Financial Results | MS | 03004, 03009, 03010, 03015, 03019 |
| 27 Feb 2026, 09:48 | Notice under Section 708A(5)(e) of the Corps Act | Securities Administration | — | 06018 |
| 27 Feb 2026, 09:47 | Application for quotation of securities - NOX | Securities Administration | — | 06020 |
| 27 Feb 2026, 09:35 | R&D rebate strengthens cash position | Company Administration | MS | 12008 |
| 27 Feb 2026, 09:06 | At-the-Market (ATM) agreement with Acuity Capital | Securities Administration | MS | 06009 |
| 11 Feb 2026, 08:17 | Sofra breakthrough science publish in major medical journal | Company Update | MS | 11001 |
| 30 Jan 2026, 09:09 | December 2025 Quarterly Activities Report and Appendix 4C | Quarterly Reports | MS | 19002, 19007 |
| 21 Jan 2026, 09:00 | HERACLES clinical trial successfully completed | Company Update | MS | 11001 |
| 2 Jan 2026, 09:16 | Notice under s708A(12C)(e) of the Corporations Act 2001 | Securities Administration | — | 06018 |
| 2 Jan 2026, 09:07 | Notification regarding unquoted securities - NOX | Securities Administration | — | 06021 |
| 2 Jan 2026, 09:02 | Notification of cessation of securities - NOX | Securities Administration | — | 06027 |
| 12 Dec 2025, 09:48 | Change of Director's Interest Notice - FB | Director Interests | — | 02009 |
| 12 Dec 2025, 09:43 | Notice under s708A(12C)(e) of the Corporations Act 2001 | Securities Administration | — | 06018 |
| 12 Dec 2025, 09:35 | Notification regarding unquoted securities - NOX | Securities Administration | — | 06021 |
| 3 Dec 2025, 08:21 | HERACLES clinical trial Update 5 | Company Update | MS | 11001 |
| 18 Nov 2025, 16:48 | Results of Meeting | Meetings & Governance | — | 08003 |
| 18 Nov 2025, 09:17 | Noxopharm 2025 AGM Corporate Presentation | Presentations | — | 03026, 15002 |
| 18 Nov 2025, 09:06 | Noxopharm 2025 AGM Chair Address | Letters & Addresses | — | 15002 |
| 17 Nov 2025, 08:27 | First dose in HERACLES clinical trial Part Two | Company Update | MS | 11001 |
| 11 Nov 2025, 08:25 | NSW Government grant for UNSW collaboration | Periodic Reports | — | 03014 |
| 5 Nov 2025, 08:51 | Second part of HERACLES clinical trial begins | Company Update | MS | 11001 |
| 30 Oct 2025, 08:58 | September 2025 Quarterly Activities Report and Appendix 4C | Quarterly Reports | MS | 19001, 19006 |
| 22 Oct 2025, 08:25 | First US patent for Sofra technology platform | Company Update | MS | 11001 |
| 13 Oct 2025, 17:55 | 2025 AGM Letter of Access, Notice of Meeting and Proxy | Meetings & Governance | — | 08001, 08004 |
| 13 Oct 2025, 17:18 | Annual Report to shareholders | Financial Results | — | 03001, 03002, 03011, 03012, 03013, 03020 |